On Tuesday, January 13, 2008 FDA issued its final Guidance to industry for the dissemination of scientific reprints and reference texts. There are a number of key differences between the draft guidance and the final guidance, reflecting some responsiveness on the part of FDA to comments received from the public, industry, and the medical community. Nonetheless, plenty of head scratching remains. We’ll seek to parse out some of these issues in the next few weeks. Read up. Go here. http://www.fda.gov/oc/op/goodreprint.html
The Next Post: Eli Lilly Settles for $1.4 Billion–But Don’t Jump to Conclusions About GRP
The Previous Post: Introduction to Good Reprint Practices
Comments Down Here
// I Accept Wit, Insight, Disagreement, and American Express.
You can follow any responses to this entry via its RSS comments feed. You may also leave a trackback by clicking this link.